In a Westlaw Today article, life sciences licensing and compliance partners Kellie Combs, Greg Levine and Josh Oyster and associate Pascale Stain discussed the federal government’s scrutiny of direct-to-consumer (DTC) prescription drug advertising.
The authors note that recent steps by the Trump administration are unprecedented in terms of their contemplated scope and raise significant questions about the U.S. Food and Drug Administration’s authority and the future of DTC prescription drug advertising. The article summarizes the latest developments and outlines potential implications for industry.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.